Chronic Co-Morbid Conditions in HIV+ U.S. Adults on Highly-Effective Anti-Retroviral Therapy (R21)

Post Date

February 4th 2010

Application Due Date

May 5th 2010

Funding Opportunity Number

RFA-NR-10-002

CFDA Number(s)

93.361

Funding Instrument Type(s)

Grant

Funding Activity Categories

Education
Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $1875000

• Award Range:

  $None - $200000

Grant Description

Purpose. This FOA issued by National Institute of Nursing Research, National Institutes of Health, solicits Research Project Grant (R21) applications from institutions/organizations proposing mechanistic projects or interventions designed to understand or intervene in chronic co-morbid conditions common to HIV+ adults living in the U.S. who are treated with anti-retroviral therapy. These conditions may be a result of anti-retroviral therapy or the HIV disease process. These same kinds of conditions may also be common in older non-infected adults, but more information is needed on the natural history, including both biological and behavioral manifestations, and appropriate intervention when HIV+ adults are affected by conditions, such as cachexia, diabetes, kidney disease, neurological changes, cardiovascular disease or cancer. Since the advent of the protease inhibitors in 1996-1997, anti-retroviral treatment options have been evolving, including the customized combination ART. It is important to evaluate this progress and identify new opportunities for research associated with the use of anti-retroviral therapies and the association of co-morbidities of HIV+ individuals as they live through middle and old age. Research exploring these issues utilizing interdisciplinary and multidisciplinary research teams is strongly encouraged, as are research teams including underrepresented, minority, disabled, or women investigators. Mechanism of Support. This FOA will utilize the R21 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-NR-10-001, that encourages applications under the R01 mechanism.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-NR-10-002.html